Radiation boosts immunotherapy in Hard-to-Treat cancers?
NCT ID NCT07269080
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tests whether giving precise, high-dose radiation to all visible tumors (up to 10) can improve the effectiveness of immunotherapy in people with advanced solid tumors that have spread. About 28 adults with 3-10 metastases will receive radiation over 3 weeks while continuing their immunotherapy. The main goal is to see if this combination leads to a significant drop in tumor DNA in the blood at 8 weeks, which could signal better cancer control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ablative radiation therapy
What this could lead to
If successful, this could show that adding targeted radiation to immunotherapy helps control metastatic cancer better than immunotherapy alone.
What could go wrong
This is a very early phase 1 pilot with only 28 participants. It may not lead to a proven treatment, and radiation can cause side effects like fatigue or tissue damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Illinois at Chicago
RECRUITINGChicago, Illinois, 60612, United States
Contact